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ABSTRACT 
Common epitopes on S-antigen (arrestin), a potent 
autoantigen inducing experimental autoimmune 
uveoretinitis (EAU), and on human tumor necrosis factor 
alpha (hTNFa) are revealed with monoclonal antibodies 
(mAb) to S-antigen, which inhibit EAU induction. The 
minimal common sequence for mAb recognition is 
GVxLxD in the S-antigenlhTNFa amino acid (aa) 
sequences. Peptides containing this sequence motif 
exhibit monocyte activating capacity analogous to the 
autocrine stimulatory capacity of hTNFa itself. In 
S-antigen this activity is located at epitope S2 
(aa residues 40 to 50), corresponding to the peptide 
PVDGVVLVDPE (peptide S2). In hTNFa the monocyte 
activating capacity correlates to aa residue 31 to 53, 
corresponding to the peptide 
RRANALLANGVELRDNQLVVPSE (peptide RRAN). 
Peptide S2 but not peptide RRAN is competing for mAbs 
S6H8 and S2D2 binding to S-antigen. Anti-idiotypic 
antibodies to S2D2 compete with peptide S2 but not 
peptide RRAN for binding to mAbs S2D2 and S6H8. 
In human retinal S-antigen epitope S2 is localized at 
the aa residues 44-54 and is cleaved in the human 
peptide 4 (aa 31-50). Competition experiments with 
peptide 4 (aa 31-50) and peptide 5 (aa 41-60) indicate 
that the C-terminal aa residues VDPD in the epitope S2 
play an important role for internal image recognition of 
the anti-idiotypic antibodies. Peptide S2 and peptide 
RRAN define common functional structures in the 
autoantigen and hTNFa molecules. The data suggest 
regulatory functions of the peptides in cytokine 
expression, network regulation and in autoimmunity. 
INTRODUCTION 
Experimental autoimmune uveoretinitis (EAU) is a 
model of ocular autoimmune disease produced in 
laboratory animals by immunization with retinal 
S-antigen (S-Ag) (1,2). S-Ag, also named arrestin or 
48K protein, is a 404 aa residue soluble protein of 
retinal photoreceptors involved in regulation of visual 
transduction (3). Experiments by Y. de Kozak et al. (4-7) 
revealed that a particular region of S-Ag is involved in 
immunoregulation of S-Ag-induced EAU. Some mAbs 
to S-Ag (S2D2, S6H8 and S7D6) prevent EAU when 
they are injected to rats at the time of immunization with 
S-Ag (4). Preimmunization with these mAbs also inhibits 
EAU induction (5), as do preimmunization with purified 
rat anti-idiotypic antibodies raised against mAb S2D2 
(6). Lewis rats, a strain highly susceptible to S-Ag- 
induced EAU, have a delayed antibody response 
against the epitope recognized by mAb S2D2, 
compared with the refractory BN strain (7). The epitope 
recognized by these mAbs is phylogenetically 
conserved in the retinal S-Ag of vertebrates and 
invertebrates (8) and is present in S-Ag-like proteins 
from several non ocular cells (9,lO) including brain 8- 
arrestin (1 1). 
We localized the epitope(s) (S2) recognized by mAbs 
S2D2, S6H8, S7D6, S8D8 and S8D1 in the N-terminus 
of the S-Ag sequence. Epitope S2 displays a common 
sequence motif with TNFa. In vitro experiments using 
synthetic peptides from bovine S-Ag (peptide S2) and 
from hTNFa (peptide RRAN) showed that these 
peptides stimulate TNFa mRNA expression in human 
monocytes (12), an effect analogous to the autocrine 
stimulatory capacity of the hTNFa molecule itself (13), 
and TNFa secretion. The characteristics of these 
epitopes were analysed in aa residue exchange 
experiments (1 4). 
common epitopes and present new data concerning 
competition of anti-idiotype S2D2 antibodies and 
peptides with S-Ag for binding to mAb S2D2. Materials 
and methods used are described in references 12 and 
14. 
We summarize here the properties of the S-AgTTNFa 
Received o n  January 13. 1992; accepted on April 20, 1992 
0 Oxford University Press 197 
Current 
Research Eye 
0 10 20 30 40 50 60 
Peptide number 
peptide 
number 
mAb 
recognition 
39 E P V D G V V  - 
40 P V D G V V L  + 
41 V D G V V L V  - 
42 D G V V L V D  + 
43 G V V L V D P  + 
44 V V L V D P E  + 
45 V L V D P E L  - 
0.25 4 I I 
0  
0 10 20 30 40 50 60 70 
Peptlde number 
Figure 1 : lmmunoreactivity profile of a) 68 
heptapeptides overlapping by six aa residues from 
bovine retinal S-Ag (N-terminal residues 1-74) and 
b) 75 heptapeptides overlapping by five aa residues 
from the complete mature hTNFa molecule. The 
S-AghTNFa common epitopes are revealed with mAb 
S6H8 (1 pg/ml) and horseradish peroxidase labeled 
protein A (Bio-Rad). 
LOCALIZATION OF CROSSREACTIVE EPITOPES IN 
The phylogenetically conserved epitope(s) S2 
recognized by mAbs S2D2, S6H8, S7D6, S8D8 and 
S8D1 was mapped to the N-terminal CNBr fragment 
CB 74 of bovine retinal S-Ag by different methods (7). 
PEPSCAN analysis allowed to compare the reactivity of 
68 synthetic heptapeptides overlapping by six aa 
residues reproducing this 74 aa N-terminal region. 
Epitope S2 was localized at the aa residues 40 to 50 
(PVDGVVLVDPE, peptide S2) as shown for mAb S6H8 
in Figure 1 a. The immunoreactivity profile for the other 
mAbS was nearly identical as for the mAb S6H8. The 
boundaries of the epitope appear to be proline in 
position 40 and glutamic acid in position 50. With the 
disappearance of proline 40, the immunoreactivity was 
negligible and reappeared with the next overlapping 
peptide starting with aspartic acid 42 (fig. 1 a). None of 
the mAbs was interacting with the presently known 
T-cell stimulating and uveitopathogenic sites which are 
located in the C-terminal part of S-Ag (CB 123, CB 35, 
CB 46) (15-21), whereas peptide S2 exhibits no 
uveitopathogenicity (unpublished result, Y. de Kozak). 
PEPSCAN-analysis of the hTNFa molecule with 
S-ANTIGEN AND HUMAN TNFa 
Table 1: Stimulation of human TNFa release. TNFa 
release was determined in the supernatant of human 
monocyte cultures after 20 h incubation with 10 pg/ml of 
the indicated preparations. TNFa concentrations were 
determined by ELISA (23). 
Preparation tested TNFa (ng / ml) 
not stimulated 
S-Ag 
peptide S2 (EPVDGVVLVDPE) 
human TNFa peptides: 
aa 31 - 42 (RRANALLANGVE) 
aa 37 - 48 (LANGVELRDNQL) 
aa 43 - 54 (LRDNQLVVPSEG) 
aa 49 - 60 (VVPSEGLYLIYS) 
aa 79 - 90 (TISRIAVSYQTK) 
aa 25 - 36 (QLQWLNRRANAL) 
aa 31 - 53 
(RRANALLANGVELRDNQLVVPSE) 
<1 .o 
5.4 
3.6 
2.5 
1.9 
1.7 
<1 .o 
<1 .o 
<1 .o 
20.4 
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these antibodies revealed a crossreactive epitope at the 
residues 39 to 45, NGVELRD (Figure 1 b), distinct from 
the epitope recognized by mAbs which inhibit TNFa 
cytotoxicity. The common motif in the sequences 40-50 
of S-Ag (PVDGVVLVDPE) and 39-45 of hTNFa 
(NGVELRD) is GVxLxD. This crossreaction was 
confirmed by Western blot analysis of TNFa with mAbs 
S2D2 and S6H8. The mAbs recognized TNFa in both 
its monomeric and dimeric forms (1 2). 
BIOLOGICAL ACTIVITY OF THE S-ANTIGEN AND 
TNFa COMMON EPITOPE 
The common recognition of the S-Ag and TNFa 
epitopes by these mAbs suggested that the 
immunomodulatory properties of the S-Ag epitope S2 
deduced from EAU suppression experiments could be 
related to regulation of TNFa production. TNFa 
synthesis by monocytes can be stimulated by TNFa 
itself (autocrine stimulation) (1 3). We studied the 
capacity of numerous peptides from hTNFa, peptide S2, 
recombinant hTNFa and native S-Ag to influence the 
expression of TNFa mRNA in the adherent fraction of 
human monocytes in vitro. Stimulation of TNFa mRNA 
synthesis was achieved by TNFa, S-Ag and peptides 
containing the common motif and derived from either 
TNFa (peptide RRAN) or S-Ag (peptide S2), but not by 
several other TNFa peptides (12). Peptide RRAN (aa 
residues 31 -53, RRANALLANGVELRDNQLVVPSE), 
which possess the autocrine stimulatory potential of 
TNFa, is part of a larger TNFa peptide (aa residues 31- 
68) with fibroblast chemotaxis inducing capacity (22). 
TNFa, S-Ag or synthetic peptides with TNFa mRNA 
inducing capacity were also capable to stimulate IL-1 p 
mRNA expression (unpublished results). In addition, 
measurable amounts of hTNFa protein were released 
after stimulation of monocytes with native S-Ag and 
peptides (Table 1). 
PEPTIDE INTERACTIONS WITH MONOCLONAL 
IDIOTYPIC ANTIBODIES TO S2D2 
We investigated two further questions: (1) Is peptide 
RRAN blocking the binding of mAbs S6H8 or S2D2 to 
S-Ag in the same way as peptide S2? (2) Are these 
peptides competing with purified rat anti-idiotypic 
antibodies (internal image of mAb S2D2) for their 
binding to mAb S2D2 and S6H8? Peptides employed in 
ELSA competition are listed in Table 2. 
Figure 2 a demonstrates that only peptide S2 and not 
peptide RRAN impairs binding of mAb S6H8 to S-Ag. 
The same result was found for S2D2. Purified anti- 
idiotypic antibodies compete also with S2 but not with 
RRAN for their binding to mAbs S6H8 (Figure 2 b) and 
S2D2. In this type of experiment we tested four other 
S-Ag peptides, among which human peptide 4 (aa 31- 
50) is cleaving epitope S2 (localized at the aa 44-54 of 
human S-Ag) and peptide 5 (aa 41-60) is containing the 
complete epitope S2. Peptide 4, which contains only the 
N-terminal residues PVDGVVL of epitope S2, does not 
compete with the internal image, whereas peptide 5 
exhibits the same competing activity as peptide S2. This 
indicates that the C-terminal residues VDPD of the 
human and/or VDPE of the bovine epitope S2 play an 
essential role in the internal image. The sequence of 
ANTIBODIES TO S-AG AND POLYCLONAL ANTI- 
Table 2: Peptides employed in competition ELISA 
species protein peptide amino acid 
name residues 
amino acid sequence 
bovine S-Ag peptide S2 39-50 E P V D G Y V L V Q P E  
human S-Ag peptide5 40-60 Q V Q P V P G Y V L V P P P L Y K G K K  
human TNFa peptide RRAN 31 -53 RRAN A L L A N G Y  E L  R R N  PL Y V j? S E 
control peptides: 
bovine S-Ag peptide M 303-320 DTNLASSTIIKEGIDKTV 
human S-Ag peptide4 30-50 GNRDYIDHVSQ V Q P V p G Y V L 
human S-Ag peptide 1 1-20 MASSGKTSKSEPNHVIFKKI 
Underlined aa residues are identical or conservative substitutions 
199 
Current 
0.9 - 
E 
C 
hl 
0.6 - 
0 
0 
0.3 - 
Eye 
Research 
VDPD can be cleaved by acidic hydrolysis between 
aspartic acid (D) and proline (P). Two control peptides, 
the uveitopathogenic peptide M (aa residues 303-320) 
from bovine S-Ag and human peptide 1 (aa residues 
1-20), had no effect in the competition experiment. 
CONCLUSIONS AND PERSPECTIVES 
Bovine S-Ag, peptide S2, human TNFa and peptide 
RRAN stimulate the expression of TNFa and IL-1 p 
mRNA and TNFa production in human monocytes. Thus 
peptide S2 and peptide RRAN define functional 
structures in the autoantigen and TNFa molecules, 
which might regulate cytokine expression. 
However the EAU inhibitory mAbs S2D2 and S6H8 
had no neutralizing effect on the induction of monocyte 
activation by S-Ag, peptide S2, peptide RRAN and 
TNFa for TNFa biosynthesis or on the cytotoxic effect of 
d 
0 
0 
0.25 1 Id P 
o !  I , ,  , , , , , , , , , 
0 1 2  3 4 5 6 7 8 9 1 0 1 1 1 2  
b, 1.2 1 
o ! , ,  , , , , , , , , , , 
0 1 2  3 4 5 6 7 8 9 1 0 1 1 1 2  
Peptide dllution 
TNFa in a bioassay. The idiotypic approach developed 
for epitope S2 will be a useful tool to characterize the 
cytokine inducing receptor(s). 
S-Ag appears to be a member of a larger protein 
family. The cytokine inducing function of epitope S2, 
whose aa sequence is identical in p-arrestin (the only 
analog whose sequence is known at the present time) 
could be involved in other autoimmune diseases and/or 
participa!e as cofactor in other pathological processes. 
The possibility of direct cytokine induction by 
autoantigens deserves investigation in other models of 
autoimmune diseases, such as EAU and EAP induced 
by rhodopsin and IRBP or experimental autoimmune 
encephalomyelitis (EAE) induced by myelin basic 
protein. The mAbs which recognize the S-Ag and TNFa 
cytokine-inducing peptides should be evaluated for their 
influence on these autoimmune diseases and on other 
TNFa-mediated experimental diseases. 
Presently human peptide RRAN, bovine peptide S2, 
human peptides 4 and 5 are tested for their effects on 
EAU induction by S-Ag immunization. The activity of 
these peptides on EAU induction and their influence on 
autoimmune network and cytokine network modulation 
could influence therapeutic approaches in autoimmune 
disease models. 
Figure 2: Competition-ELISA 
a) on S-Ag coated plates (O.lpg/well) using a defined 
concentration of affinity purified mAb S6H8. MAb 
binding was revealed with the anti-mouse 
biotidperoxidase-streptavidin-complex system 
(Amersham). 
Competing peptides: 
0 Peptide S2 (EPVDGVVLVDPE) 
Peptide R RAN (R RAN ALL AN GVEL RD NQLVV PS E ). 
b) on affinity purified mAb S6H8 (0.1 pg/well) using a 
defined concentration of rat-anti-idiotypic antibodies. 
Anti-Id antibody binding was revealed with a 
peroxidase-labeled mouse anti-rat kappa chain specific 
mAb (MARK, Immunotech, Luminy, Marseille, France). 
Competing peptides: 
x peptide S2 (EPVDGVVLVDPE) 
0 peptide 5 (QVQPVDGVVLVDPDLVKGK) 
o peptide 1 (MASSGKTSKSEPNHVIFKKI) 
peptide 4 (GNRDYIDHVSQVQPVDGVVL) 
+ peptide RRAN (RRANALLANGVELRDNQLVVPSE) 
A peptide M (DTNLASSTIIKEGIDKTV). 
Competing peptides were serially twofold diluted 
starting with an initial peptide concentration of 1000 
molar excess over the coated S-Ag or 10000 molar 
excess over the coated mAb S6H8. 
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